Lakefront Biotherapeutics NV (GLPGN) Stock Price & Analysis
GLPGN Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- MXN 40.12B
- Enterprise Value
- -MXN 394.90M
- Total Cash (Recent Filing)
- MXN 2.98B
- Total Debt (Recent Filing)
- MXN 6.43M
- Price to Earnings (P/E)
- 3.9
- Beta
- N/A
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -15.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Near-zero leverage and a large equity base provide substantial financial resilience. This strengthens the company’s ability to fund operations and investment internally, absorb business volatility, and preserve strategic flexibility without depending heavily on creditors.
Strong Profitability
Strong TTM net and EBIT margins indicate that the current revenue mix is converting efficiently into earnings. If maintained, this profitability can support reinvestment, strengthen internal funding capacity, and provide a durable base for future earnings generation.
High Gross Margins
Consistently very high gross margins suggest a favorable revenue mix and meaningful value retained after direct costs. This creates operating leverage potential and gives the company more capacity to support research, commercial investment, and profitability over time.
Bears Say
Persistent Cash Burn
Negative operating and free cash flow in every period shows that reported profitability is not currently translating into self-funded operations. Continued cash burn can consume the balance sheet, limit investment flexibility, and increase dependence on existing financial resources.
Uneven Revenue Momentum
The TTM revenue decline following a sharp prior-year increase indicates an unpredictable top-line trajectory. Uneven growth makes forward earnings less reliable, complicates resource planning, and may reduce the company’s ability to sustain its recent profitability gains.
Earnings Volatility
The shift from losses in 2021–2022 to strong TTM earnings demonstrates meaningful earnings volatility. Although the recent improvement is positive, inconsistent historical performance makes it harder to establish durable returns and increases the importance of maintaining current profitability.
Lakefront Biotherapeutics NV News
GLPGN FAQ
What is Lakefront Biotherapeutics NV’s market cap?
When is Lakefront Biotherapeutics NV’s upcoming earnings report date?
How were Lakefront Biotherapeutics NV’s earnings last quarter?
Is Lakefront Biotherapeutics NV overvalued?
Does Lakefront Biotherapeutics NV pay dividends?
What is Lakefront Biotherapeutics NV’s EPS estimate?
How many shares outstanding does Lakefront Biotherapeutics NV have?
What happened to Lakefront Biotherapeutics NV’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lakefront Biotherapeutics NV?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Henry Gosebruch
- Employees
- 452
- Website
- lakefrontbio.com
- Address
- Schalienhoevedreef 20 T, Mechelen, 2800, BE